Michael J. Fox Foundation partners with 23andMe for precision medicine project on Parkinson’s

First cancer. Now, Parkinson’s?

The idea that one disease is actually several, each driven by its own genetics and differing in everything from age of onset to response to drugs, made cancer the poster child for precision medicine. Now, a $4 million study announced on Monday aims to see whether a genetically informed precision-medicine approach might work for Parkinson’s, too.

The study is a partnership between the Michael J. Fox Foundation for Parkinson’s Research and the genetic testing company 23andMe. One goal: to identify new drug candidates.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In